ArticleJournal of neurology2026
Evaluating the neurofilament light chain-derived gap between biological and chronological age in multiple sclerosis and controls.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveTo compare chronological age and neurofilament light chain (NfL)-derived age in people with multiple sclerosis (pwMS) and controls, and to explore clinical correlates of the NfL age gap.
methodsWe conducted a real-world, retrospective analysis including 792 pwMS (without evidence of clinical or MRI activity in the previous year and during follow-up) and 302 controls. NfL-derived age was computed using established age-adjusted reference. We used logistic regression models to compare pwMS and controls in chronological and NfL-derived age groups, and linear regression models to evaluate the associations of chronological age and NfL-derived age with clinical variables (Expanded Disability Status Scale (EDSS), disease duration, disease course, disease modifying treatment (DMT) class, number of previous DMTs) and the associations between the NfL age gap (difference between biological and chronological age) and clinical variables.
resultsPwMS showed a higher likelihood than controls of having a NfL-derived age above their chronological age (OR = 1.44;95%CI 1.10-1.87; p = 0.007). EDSS, disease duration, and progressive disease course were associated with both chronological and NfL-derived age (all p < 0.001). The NfL age gap showed independent associations with EDSS (Coeff = 0.147; 95%CI 0.097-0.197; p < 0.001), progressive disease course (Coeff = 0.34; 95%CI 0.16-0.53; p < 0.001), and number of previous DMTs (Coeff = 0.06; 95% CI 0.01-0.11; p = 0.028), but not with disease duration or DMT class. Similar results were observed in a sub-analysis excluding pwMS with EDSS progression.
conclusionsMS is associated with a shift in age-associated NfL trajectory, with an older biological profile especially in pwMS with greater disability and progressive course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.